Caveolin-1 Expression Predicts Efficacy of Weekly Nab-Paclitaxel Plus Gemcitabine for Metastatic Breast Cancer in the Phase II Clinical Trial

BMC Cancer - United Kingdom
doi 10.1186/s12885-018-4936-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Performance Status Dynamics During Treatment With Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone for Metastatic Pancreatic Cancer

Cancer Management and Research
Oncology
2018English

P1.01-48 Nab-Paclitaxel Plus Gemcitabine in Advanced NSCLC After Platinum-Based Chemotherapy: Final Results and Caveolin-1 Expression

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2015English

Phase I–II Trial of Prolonged Gemcitabine Infusion Plus Paclitaxel as a Biweekly Schedule for Advanced Breast Cancer Patients Pretreated With Anthracyclines

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2010English

Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With Nab-Paclitaxel and Gemcitabine

Pancreas
Internal MedicineEndocrinologyHepatologyMetabolismDiabetes
2017English

A Phase I/Ii Study of Weekly Nab-Paclitaxel Plus Cisplatin in Chemotherapy-Naïve Patients With Advanced Non-Small-Cell Lung Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

S‐1 Plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial

Oncologist
Cancer ResearchMedicineOncology
2019English

Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Role of Nab-Paclitaxel in Metastatic Breast Cancer: A Meta-Analysis of Randomized Clinical Trials

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy